fundvisualizer.com

Fidelity Advisor® Biotechnology AFBTAX

Performance (before sales charge)

As of 12/31/2022

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 11/30/2022
Stock
90.46%
Non-U.S. Stock
6.91%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
0.07%
Other
2.55%

Due to rounding, percentages may not equal 100%.

Sectors

As of 11/30/2022

Basic materials

0.00%

Consumer cyclical

0.00%

Financial services

0.00%

Real estate

0.00%

Consumer defensive

0.00%

Health care

97.27%

Utilities

0.00%

Communication services

0.00%

Energy

0.00%

Industrials

0.00%

Technology

0.00%

Top 10 holdings

As of 11/30/2022

AbbVie Inc
19.89%
Regeneron Pharmaceuticals Inc
10.08%
Vertex Pharmaceuticals Inc
8.02%
Alnylam Pharmaceuticals Inc
6.57%
argenx SE ADR
4.68%
Ascendis Pharma A/S ADR
3.47%
Blueprint Medicines Corp
3.08%
Seagen Inc Ordinary Shares
3.03%
Cytokinetics Inc
3.02%
Gilead Sciences Inc
2.37%
Fund assets

$1.77 Billion

Share class

A

Morningstar category

Health

Expense ratio

1.00%

Investment objective

Specialty - Health

Documents